Is thyroid nodule location associated with malignancy risk?

Valeria Ramundo¹, Livia Lamartina¹, Rosa Falcone¹, Laura Ciotti¹, Cristiano Lomonaco¹, Marco Biffoni², Laura Giacomelli², Marianna Maranghi¹, Cosimo Durante¹, Giorgio Grani¹

¹Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome; ²Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy

Purpose: Nodules located in the upper pole of the thyroid may carry a greater risk for malignancy than those in the lower pole. We conducted a study to analyze the risk of malignancy of nodules depending on location.

Methods: The records of patients undergoing thyroid-nodule fine-needle aspiration cytology (FNAC) at an academic thyroid cancer unit were prospectively collected. The nodules were considered benign in cases of a benign histology or cytology report, and malignant in cases of malignant histology. Pathological findings were analyzed based on the anatomical location of the nodules, which were also scored according to five ultrasonographic classification systems.

Results: Between November 1, 2015 and May 30, 2018, 832 nodules underwent FNAC, of which 557 had a definitive diagnosis. The prevalence of malignancy was not significantly different in the isthmus, right, or left lobe. Among the 227 nodules that had a precise longitudinal location noted (from 219 patients [155 females], aged 56.2±14.0 years), malignancy was more frequent in the middle lobe (13.2%; odds ratio [OR], 9.74; 95% confidence interval [CI], 1.95 to 48.59). This figure was confirmed in multivariate analyses that took into account nodule composition and the Thyroid Imaging, Reporting, and Data System (TIRADS) classification. Using the American College of Radiologists TIRADS, the upper pole location also demonstrated a slightly significant association with malignancy (OR, 6.92; 95% CI, 1.02 to 46.90; P=0.047).

Conclusion: The risk of thyroid malignancy was found to be significantly higher for mid-lobar nodules. This observation was confirmed when suspicious ultrasonographic features were included in a multivariate model, suggesting that the longitudinal location in the lobe may be a risk factor independently of ultrasonographic appearance.

Keywords: Thyroid Imaging, Reporting, and Data System; Thyroid nodule; Cytology; Location; Neoplasms

Introduction

Thyroid nodules may affect up to 65% of the general population, and this high rate is mainly due to the increasing detection of nodules through the routine use of ultrasonography in clinical practice [1]. Approximately 16 million individuals in the United States are estimated to have a palpable nodule, and up to 219 million are estimated to have an ultrasound-detectable nodule [2]. Ultrasonography
(US) is the primary tool for the initial cancer risk stratification of thyroid nodules and the subsequent decision of whether to order a fine-needle aspiration biopsy [2–4]. A diagnostic US report should include a description of the background thyroid parenchyma, nodule location, size, US features, and a survey of the cervical lymph nodes [5,6].

Various US characteristics of nodules, such as microcalcifications; hypoechogenicity; irregular, microlobulated, or infiltrative margins; and taller-than-wide shape, are all associated with greater malignancy risk, but no prior study has examined the risk of malignancy in relation to location in the upper versus lower pole of the thyroid, except for a poster presented at the American Association of Clinical Endocrinologists (AACE) 2018 Annual Scientific and Clinical Congress showing that nodules located in the upper pole of the thyroid gland may carry a greater risk for malignancy than those in the lower pole [7]. The aim of this study was to evaluate the frequency of thyroid nodules in various parts of the gland and to correlate the anatomical location with the risk of malignancy.

**Materials and Methods**

All records of patients who underwent fine-needle aspiration cytology (FNAC) for thyroid nodules at an academic referral center between November 1, 2015 and May 30, 2018 were prospectively collected. The study was approved by the Institutional Review Board and all patients signed an informed consent form. Neck US was performed by a physician with specific experience and training in thyroid US. The same sonographic equipment (HI VISION Avius, Hitachi Medical Corporation, Inc., Tokyo, Japan) with a high-frequency linear transducer (12–18 MHz) with harmonic imaging was used to image the neck in both transverse and longitudinal views with grayscale and color Doppler imaging. During the real-time US assessment, the site (right or left lobe) and size (transverse, anteroposterior, and longitudinal diameters) of the thyroid nodules subjected to FNAC were recorded.

The US characteristics were evaluated and classified according to five US classification systems: the American College of Radiology (ACR) Thyroid Imaging, Reporting, and Data System (TI-RADS) [8,9], the American Association of Clinical Endocrinologists/American College of Endocrinology/Associazione Medici Endocrinologi guidelines [4], the American Thyroid Association guidelines [3], the European Thyroid Association TI-RADS [6], and the Korean Society of Thyroid Radiology TI-RADS [10]. In each system, a set of US features defines a risk class that represents the likelihood that a nodule is malignant. Given the interobserver variability described for echogenicity [11], other suspicious features [12], and TI-RADS classifications [13,14], the evaluation was performed jointly by two examiners (each with 8 years of thyroid imaging experience) after specific training [13].

Nodule cytology was classified according to the Italian Consensus for Thyroid Cytopathology [15]. This scheme is similar to the Bethesda classification system [16]. A composite reference standard was applied. Nodules were considered benign in cases of a benign histology or cytology report, and malignant in cases of malignant histology. Nodules with TI-RADS I, TI-RADS A, and TI-RADS B cytology (similar to Bethesda I, III, and IV classes) without a final histologic diagnosis were excluded (Fig. 1).

Using this entire cohort, we studied the prevalence of malignancy according to location (isthmic, right lobe, or left lobe): these 557 nodules constituted the cohort 1. On that basis, we previously conducted a study to evaluate US features, not location, and those results have already been published [17]. Since the precise location of the lesions was not the main focus of the previous study, the original examiner reported the longitudinal location in the gland (upper, middle, or inferior pole) only for a subset of nodules. Furthermore, nodules involving the whole lobe and isthmic nodules were excluded. In the present study, cytological and pathological findings were then analyzed and correlated with the craniocaudal
Thyroid nodule location and malignancy risk

location of thyroid nodules in the gland (227 nodules that composed the cohort 2) (Fig. 1).

Statistical analysis
Data were analyzed with the IBM SPSS Statistics package version 25.0 (IBM Corp., Armonk, NY, USA) and Microsoft Office Suite. Descriptive data are reported as mean±standard deviation. Univariate and multivariate logistic regression analyses were performed to estimate the odds ratios (ORs) of malignancy and their 95% confidence intervals (95% CIs).

Results
During the study period, 832 thyroid nodules underwent US-guided FNAC, of which 557 had a definitive final diagnosis (513 benign, 44 malignant). In our previous cohort study, we analyzed the malignancy rate according to location in the isthmus, right lobe, or left lobe, and found no differences between the 2 lobes and the isthmus (Table 1).

Of the nodules with a definitive final diagnosis, 227 had a precise longitudinal location noted within the lobes. These nodules were from 219 patients (64 males, 155 females), aged 56.2±14.0 years (range, 17 to 85 years). The mean maximum diameter of the thyroid nodules was 17.6±7.8 mm (range, 6.0 to 56.4 mm). The anatomical distribution of thyroid nodules showed a higher prevalence in the inferior pole (57.3%), with no differences between the two lobes, as shown in Table 3. Among the 12 malignant thyroid nodules, the classic variant of papillary thyroid cancer (PTC) was found in 10 cases (83.3%), the follicular variant of PTC in one case (8.3%), and follicular thyroid cancer in one case (8.3%).

In our study, thyroid malignancy was more frequent in the middle lobe (13.2%; OR, 9.74; 95% CI, 1.95 to 48.59) (Table 2). This figure was confirmed in multivariate analyses taking into account either solid composition of the nodule (Table 3) or the high-risk classification according to the five US classification systems (Table 4). The models remained separate (classifications and solid composition of the nodule were not included in the same model) because composition is an item taken into account to classify nodules in many of these systems. These systems differ from each other in their structure, interobserver variability [13,14], consistency over time [18], and number of suggested biopsies [17]. However, increased odds for malignancy were confirmed for mid-lobar nodules, after adjusting for high-risk classification according to all five systems (Table 4).

Interestingly, in a multivariate analysis including location and an ACR score of TR5 (highly suspicious), the classification had an OR for malignancy of 9.19 (95% CI, 2.45 to 34.52), and an increased OR for malignancy was confirmed for nodules with a mid-lobar location (OR, 7.70; 95% CI, 1.47 to 40.38). The upper pole location also demonstrated a significant association with malignancy (OR, 6.92; 95% CI, 1.02 to 46.90).

Table 1. Pathological diagnoses according to isthmic, right, or left location

<table>
<thead>
<tr>
<th>Location</th>
<th>Final diagnosis, n (%)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isthmus (n=40)</td>
<td>39 (97.5) 1 (2.5)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Right lobe (n=240)</td>
<td>217 (90.4) 23 (9.6)</td>
<td>4.13 (0.54–31.50)</td>
<td></td>
</tr>
<tr>
<td>Left lobe (n=227)</td>
<td>257 (92.8) 20 (7.2)</td>
<td>3.04 (0.40–23.26)</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Pathological diagnoses according to thyroid nodule location

<table>
<thead>
<tr>
<th>Location</th>
<th>Final diagnosis, n (%)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper pole (n=44, 19.4%)</td>
<td>41 (93.2) 3 (6.8)</td>
<td>4.68 (0.76–29.00)</td>
<td>0.097</td>
</tr>
<tr>
<td>Middle lobe (n=53, 23.3%)</td>
<td>46 (86.8) 7 (13.2)</td>
<td>9.74 (1.95–48.59)</td>
<td>0.006</td>
</tr>
<tr>
<td>Inferior pole (n=130, 57.3%)</td>
<td>128 (98.5) 2 (1.5)</td>
<td>1</td>
<td>–</td>
</tr>
</tbody>
</table>

Table 3. Univariate and multivariate analysis of the relationship between thyroid nodule location and malignancy

<table>
<thead>
<tr>
<th>Location</th>
<th>Univariate OR (95% CI)</th>
<th>P-value</th>
<th>Multivariate* OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper pole</td>
<td>4.68 (0.76–29.00)</td>
<td>0.097</td>
<td>4.53 (0.71–29.07)</td>
<td>–</td>
</tr>
<tr>
<td>Middle lobe</td>
<td>9.74 (1.95–48.59)</td>
<td>0.006</td>
<td>8.63 (1.67–44.53)</td>
<td>0.010</td>
</tr>
<tr>
<td>Solid nodule</td>
<td>–</td>
<td></td>
<td>9.26 (1.94–44.31)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

The multivariate model included longitudinal location and solid composition of the nodule.

*The multivariate model included longitudinal location and solid composition of the nodule.

Discussion
No previous study in the literature has examined the risk of thyroid malignancy according to the anatomical site of thyroid nodules, except for a preliminary report [7]. In our study, an analysis of the distribution of thyroid nodules showed a higher prevalence of
lesions in the inferior pole, with no differences between the two lobes. These data are consistent with the reports of other authors [19,20]. The possible causes of this tropism are still unknown and have not been systematically assessed in the literature, except for medullary thyroid cancer (no cases in this study), which is commonly located in the middle-upper portions of the lobes due to the normal aggregation of parafollicular C-cells [21]. However, no similar anatomical explanations are envisioned for papillary and follicular thyroid cancer. It is possible that nodules are in general more frequent in the inferior pole [19,20,22]; as a result, the relative frequency of malignant nodules in this area appears to be lower. Interestingly, the location of PTC has also been proposed as a prognostic factor, as lymph node metastasis has been reported to be more common in cases of mid-lobar [23] or upper pole [24] cancers.

This is a brief report reporting preliminary observations, with some limitations. First, the location of thyroid nodules was noted and reported only in a random subset of cases. Furthermore, a composite reference standard was used, with possible false-positive and false-negative cases. Larger studies, specifically designed to investigate this issue, are needed to better investigate and confirm these data.

In conclusion, the risk of thyroid malignancy was found to be significantly higher for nodules located in the middle lobe. This observation was also confirmed when including solid composition and TIRADS classification as high-risk in a multivariate model, suggesting that a mid-lobe location (or mid-lobe and upper pole location for ACR TIRADS high-risk lesions) may be a risk factor independent of US appearance; therefore, it should be considered for potential inclusion in US classification systems.

### Table 4. Multivariate analysis assessing malignancy risk according to thyroid nodule location, adjusting for high-risk estimation according to five ultrasonographic classification systems

<table>
<thead>
<tr>
<th>Classification</th>
<th>ACR TIRADS</th>
<th>AACE</th>
<th>ATA</th>
<th>EU-TIRADS</th>
<th>K-TIRADS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Upper pole</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>6.92 (1.02–46.90)</td>
<td>5.80 (0.91–37.03)</td>
<td>5.88 (0.91–38.12)</td>
<td>6.01 (0.94–38.59)</td>
<td>4.81 (0.75–30.79)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.047</td>
<td>0.063</td>
<td>0.063</td>
<td>0.059</td>
<td>0.097</td>
</tr>
<tr>
<td><strong>Middle lobe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>7.70 (1.47–40.38)</td>
<td>10.12 (2.00–51.16)</td>
<td>9.26 (1.81–47.44)</td>
<td>10.06 (1.99–50.86)</td>
<td>7.55 (1.45–39.31)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.016</td>
<td>0.005</td>
<td>0.008</td>
<td>0.005</td>
<td>0.016</td>
</tr>
<tr>
<td><strong>High-risk classification</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>9.19 (2.45–34.52)</td>
<td>3.14 (0.92–10.74)</td>
<td>5.54 (1.50–20.46)</td>
<td>3.29 (0.96–11.31)</td>
<td>7.41 (1.95–28.12)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.001</td>
<td>0.068</td>
<td>0.01</td>
<td>0.059</td>
<td>0.003</td>
</tr>
</tbody>
</table>

The multivariate model included longitudinal location and high-risk status in the ultrasonographic classification systems. High-risk classification and solid composition of the nodule were not included in the same model, because composition is one of the items taken into account to classify nodules in some of the classification systems. ACR, American College of Radiology; TIRADS, Thyroid Imaging, Reporting, and Data System; AACE, American Association of Clinical Endocrinologist; ATA, American Thyroid Association; EU-TIRADS, European TIRADS; K-TIRADS, Korean TIRADS; OR, odds ratio; CI, confidence interval.

### Conflict of Interest
No potential conflict of interest relevant to this article was reported.

### Acknowledgments
The study was funded by a Research Starter Grant of the University of Rome, Sapienza (to GG, AR216154C9B479B2).

### References
4. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L,


